MEF2D overexpression contributes to the progression of osteosarcoma

Gene

Volumn 563, Issue 2, 2015, Pages 130-135

  Yu, Haichi ^a   Sun, Honghui ^a   Bai, Yunshen ^a   Han, Jinhua ^a   Liu, Guomin ^a   Liu, Yi ^b   Zhang, Nan ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Cell cycle; MEF2D; MiR 144; Osteosarcoma

Indexed keywords

MEF2D TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 144; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MEF2D PROTEIN, HUMAN; MIRN144 MICRORNA, HUMAN; MYOCYTE ENHANCER FACTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; DISEASE COURSE; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FIBROBLASTS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; OSTEOSARCOMA;

EID: 84926983534     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.03.046     Document Type: Article

References (12)

1. Heymann D., Redini F. Targeted therapies for bone sarcomas. Bonekey Rep. 2013, 2:378.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
3. Kramer I., Baertschi S., Halleux C., Keller H., Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J. Bone Miner. Res. 2012, 27:360-373.
4. Li C., Cheng Q., Liu J., Wang B., Chen D., Liu Y. Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma. Mol. Cell. Biochem. 2012, 364:337-344.
5. Ma L., Liu J., Liu L., Duan G., Wang Q., Xu Y., Xia F., Shan J., Shen J., Yang Z., Bie P., Cui Y., Bian X.W., Prieto J., Avila M.A., Qian C. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014, 74:1452-1462.
6. McKinsey T.A., Zhang C.L., Olson E.N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 2002, 27:40-47.
7. Prima V., Hunger S.P. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 2007, 21:2470-2475.
8. Prima V., Gore L., Caires A., Boomer T., Yoshinari M., Imaizumi M., Varella-Garcia M., Hunger S.P. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 2005, 19:806-813.
9. Shalizi A., Bilimoria P.M., Stegmuller J., Gaudilliere B., Yang Y., Shuai K., Bonni A. PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic morphogenesis. J. Neurosci. 2007, 27:10037-10046.
10. Stephens A.S., Stephens S.R., Hobbs C., Hutmacher D.W., Bacic-Welsh D., Woodruff M.A., Morrison N.A. Myocyte enhancer factor 2c, an osteoblast transcription factor identified by dimethyl sulfoxide (DMSO)-enhanced mineralization. J. Biol. Chem. 2011, 286:30071-30086.
11. Yan Z., Wang J., Wang C., Jiao Y., Qi W., Che S. miR-96/HBP1/Wnt/beta-catenin regulatory circuitry promotes glioma growth. FEBS Lett. 2014, 588:3038-3046.
12. Zhang M., Truscott J., Davie J. Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol. Cancer 2013, 12:150.